Proteolysis-targeting chimera (PROTAC) and other targeted protein degradation (TPD ... However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the ...

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...

Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...

Representatives from four leading companies highlight emerging basic and clinical research that drives renewed optimism.

A PROTAC is a heterobifunctional molecule that can bind both a target protein and an E3 ubiquitin ligase to facilitate the formation of a ternary complex, leading to ubiquitination and ultimate ...

Our group's research efforts aim to uncover novel cancer treatments and centre around three main themes: PROTAC, Molecular Glue Degraders, and novel E3 ligases. My earlier research in PROTAC ...